---
title: "Is Retatrutide Approved? Current FDA Status and Availability (May 2026)"
description: "Retatrutide is NOT FDA-approved as of May 2026. Phase 3 TRIUMPH-1 (May 2026) showed -28.3% weight loss; TRIUMPH-4 showed -28.7%; TRANSCEND-T2D-1 met diabetes endpoints. NDA expected late 2026/Q1 2027; approval 2027-2028."
url: https://retatrutide.med/knowledge-base/is-retatrutide-approved
date: 2025-08-01
lastUpdated: 2026-05-26
author: "retatrutide.med Editorial"
topic: "development"
evidenceLevel: "moderate"
tags: ["approval", "FDA", "regulatory", "TRIUMPH", "Phase 3", "availability", "compounded", "investigational", "TRIUMPH-1", "TRIUMPH-4", "retatrutide approved", "retatrutide FDA approval"]
source: retatrutide.med
sourceType: "knowledge base article"
license: CC-BY-NC-SA-4.0
canonical: https://retatrutide.med/knowledge-base/is-retatrutide-approved
---
## The Short Answer

**No, retatrutide is not approved.** As of May 2026, retatrutide has not been approved by any regulatory authority in the world, including the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA), or any other national regulatory body. It remains an investigational compound in Phase 3 clinical development. It has no brand name, is not available by prescription, and cannot be legally purchased from any pharmacy or licensed distributor.

This is one of the most frequently asked questions about retatrutide, driven by widespread media coverage of three positive Phase 3 readouts in 2025-2026: **TRIUMPH-4** (December 2025, -28.7% weight loss at 12 mg in obesity with knee OA), **TRANSCEND-T2D-1** (April 30, 2026, in Eli Lilly Q1 earnings: HbA1c -1.7 to -2.0 percentage points and -11.1 to -16.6 kg weight loss in T2D), and most recently **TRIUMPH-1** (May 21, 2026, -28.3% weight loss at 12 mg over 80 weeks in 2,339 adults with obesity but no diabetes). Even with three positive pivotal readouts in hand, the drug development process requires NDA submission and FDA review before approval — and Eli Lilly has not yet filed.

## Why Is Retatrutide Not Yet Approved?

### The Drug Development Process

To understand why retatrutide is not yet available, it is helpful to understand the standard drug development pathway. In the United States, the FDA requires that new drugs pass through a series of clinical development phases before they can be considered for approval:

- **Phase 1**: Small studies in healthy volunteers or patients to assess safety, tolerability, and pharmacokinetics. Retatrutide completed Phase 1 studies.
- **Phase 2**: Moderate-sized studies to evaluate efficacy, determine optimal dosing, and further characterize safety. Retatrutide completed Phase 2 studies with positive results published in the New England Journal of Medicine (obesity) and The Lancet (type 2 diabetes).
- **Phase 3**: Large, pivotal studies involving thousands of participants designed to confirm efficacy, establish the safety profile in a broader population, and generate the data required for regulatory submission. **Retatrutide is currently in this phase.**
- **Regulatory review**: After Phase 3 completion, the sponsor (Eli Lilly) submits a New Drug Application (NDA) or Biologics License Application (BLA) to the FDA, which then reviews the complete data package and decides whether to approve the drug.

Retatrutide is currently in Phase 3, meaning it has not yet completed the full set of pivotal studies required for regulatory submission. No NDA or BLA has been filed with the FDA or any other regulatory agency.

### What Phase 3 Must Demonstrate

The Phase 3 program must accomplish several objectives before regulatory submission can proceed:

- **Confirm efficacy** in large, diverse patient populations for each intended indication (obesity, type 2 diabetes, and potentially MASH)
- **Establish the safety profile** with sufficient statistical power to detect uncommon adverse events — including characterizing the dysesthesia signal found in TRIUMPH-4
- **Characterize long-term effects** over treatment durations longer than the 48 weeks studied in Phase 2
- **Identify the optimal dose and escalation regimen** for clinical use
- **Evaluate effects in special populations** including older adults, patients with renal impairment, and patients with cardiovascular disease

## What "Phase 3" Means for Patients

Phase 3 is the final stage of clinical development before regulatory submission. Being in Phase 3 means:

- **The drug has shown promise**: Phase 2 data were positive enough to justify the substantial investment in a large Phase 3 program
- **Large-scale testing is underway**: Thousands of participants are being treated across multiple countries and clinical sites
- **Approval is not guaranteed**: Historically, approximately 50-60% of drugs that enter Phase 3 ultimately receive FDA approval. Positive Phase 3 results increase the probability substantially, but unforeseen safety issues, insufficient efficacy, or manufacturing problems can still prevent approval
- **The timeline is measurable**: Unlike earlier development stages, Phase 3 trials have defined endpoints and estimated completion dates, making timeline projections more reliable

For patients, Phase 3 status means the drug is progressing but is still years away from commercial availability.

## The TRIUMPH Phase 3 Program

### Program Overview

Eli Lilly's Phase 3 clinical program for retatrutide is known as TRIUMPH. It is one of the largest metabolic drug development programs currently underway, consisting of multiple clinical trials evaluating retatrutide across different indications and patient populations:

- **TRIUMPH-1 through TRIUMPH-4**: Four pivotal trials evaluating retatrutide for obesity and weight-related conditions
- **TRIUMPH-Outcomes**: ~10,000-patient cardiovascular outcomes trial (CVOT)
- **TRANSCEND**: Type 2 diabetes program (TRANSCEND-T2D-1, TRANSCEND-T2D-2 head-to-head vs semaglutide, and TRANSCEND-CKD)
- **SYNERGY / MACELD**: Trials for metabolic dysfunction-associated steatohepatitis (MASH), with histological endpoints

### TRIUMPH-4: First Phase 3 Results (December 2025)

TRIUMPH-4 was the first trial in the program to report results. It enrolled 445 adults with obesity and knee osteoarthritis and demonstrated:

- **Retatrutide 12 mg: -28.7% mean weight loss** at 68 weeks
- **Retatrutide 9 mg: -26.4% mean weight loss** at the same timepoint
- **99% of participants at 12 mg achieved at least 5% weight loss**
- **75% reduction in knee osteoarthritis pain scores**
- **New safety finding: dysesthesia** (numbness, tingling, burning sensations) in 20.9% at 12 mg versus 0.7% placebo

### TRANSCEND-T2D-1 (March 19, 2026)

Positive topline results were announced via Eli Lilly press release on March 19, 2026 and elaborated at the Q1 2026 earnings call on April 30:

- **HbA1c reductions of 1.7-2.0 percentage points** across doses — glycemic control comparable to tirzepatide
- **Weight loss of 11.5-16.8%** across doses (n=537, 40 weeks)
- Dysesthesia 2.3-4.5% across doses (lower than the obesity trials)
- The combination of glycemic control plus additional weight loss is what management framed as the clinically meaningful retatrutide differentiator versus tirzepatide in the T2D population

### TRIUMPH-1: Pivotal Obesity Trial (May 21, 2026)

The largest readout to date — the obesity-indication-anchor trial:

- **Retatrutide 12 mg: -28.3% mean weight loss (efficacy estimand)** at 80 weeks in 2,339 adults with obesity but no diabetes
- **45.3% of 12 mg participants achieved ≥30% weight loss** — bariatric-surgery territory
- **65.3% ended the trial with BMI <30** (no longer obese)
- All three doses (4 mg, 9 mg, 12 mg) met the primary endpoint
- **104-week extension hit -30.3%** in the BMI ≥35 subgroup
- **Dysesthesia at 12 mg: 12.5%** — substantially lower than TRIUMPH-4's 20.9% at the same dose
- **Discontinuation due to AEs at 12 mg: 11.3%** — also lower than TRIUMPH-4's 18.2%

### Remaining Trials

As of May 2026, TRIUMPH-2 (obesity + type 2 diabetes) is expected to read out in Q2-Q3 2026, and TRIUMPH-3 (obesity + established cardiovascular disease) in Q3-Q4 2026. The TRIUMPH-Outcomes CVOT and SYNERGY/MACELD MASH trials run on longer timelines.

## Expected Timeline for Approval

### Realistic Projections

Based on the current status of the TRIUMPH program:

| Milestone | Estimated Timing |
|---|---|
| Additional Phase 3 data readouts | Late 2026 - 2027 |
| NDA preparation and submission | Late 2026 |
| FDA review period | 6-12 months after submission |
| Potential FDA approval (earliest) | Mid-2027 (optimistic) |
| Potential FDA approval (base case) | Late 2027 - Early 2028 |
| Commercial availability | Shortly after approval |

These projections carry significant uncertainty. Delays in enrollment, unexpected safety findings, FDA requests for additional data, or manufacturing issues could all extend the timeline. Conversely, breakthrough therapy designation or rolling submission could shorten it.

### Comparison to Tirzepatide's Timeline

Eli Lilly's tirzepatide (Mounjaro/Zepbound) provides a useful comparison:

- SURMOUNT-1 Phase 3 obesity data published: mid-2022
- Zepbound FDA approval for obesity: November 2023
- **Time from Phase 3 data to obesity approval: approximately 17 months**

However, tirzepatide benefited from prior diabetes approval (Mounjaro, May 2022), which established its safety database. Retatrutide does not have this advantage, as it has never been approved for any indication.

### FDA Review Process

Once Eli Lilly submits an NDA, the FDA review follows a structured process:

- **60-day filing review**: FDA determines if the application is complete enough to accept
- **Standard Review**: 10-12 months from acceptance to decision
- **Priority Review**: 6-8 months, granted when the drug offers significant improvement over existing treatments
- **Advisory Committee**: The FDA may convene external experts to evaluate the benefit-risk profile, particularly given the novel triple receptor mechanism and the dysesthesia signal

## How to Access Retatrutide Today

### Clinical Trials Are the Only Legitimate Route

The only way to receive retatrutide is through enrollment in an authorized clinical trial. Steps to explore this option:

1. Visit **ClinicalTrials.gov** and search for "retatrutide" or "LY3437943"
2. Review the list of active trials and their eligibility criteria
3. Discuss potential participation with your healthcare provider
4. Contact the study sites listed for trials that may be appropriate

Clinical trial participation involves its own considerations: randomization (you may receive placebo), strict visit schedules, monitoring requirements, and eligibility criteria that may exclude many individuals.

### What Clinical Trial Participation Involves

Participants in TRIUMPH trials typically undergo:

- Screening assessments to verify eligibility
- Regular clinic visits (often monthly) for injections, lab work, and assessments
- Possibility of receiving placebo rather than active drug
- Long treatment periods (68+ weeks for most pivotal trials)
- Follow-up after treatment completion

## Warning About Illegitimate Sources

### The Problem of Gray-Market Peptides

The significant public interest in retatrutide has created a market for unregulated peptide products claiming to be retatrutide. These products are available from various online sources, including research chemical suppliers, compounding pharmacies operating outside standard regulatory oversight, and international vendors. **These products pose significant risks:**

- **No quality assurance**: Unregulated products are not manufactured under Good Manufacturing Practice (GMP) conditions. There is no guarantee of purity, potency, sterility, or even identity. Independent analyses of gray-market peptides have consistently found contamination, incorrect potency, and mislabeling.
- **Unknown safety**: Without manufacturing controls, these products may contain impurities, endotoxins, or degradation products that pose health risks independent of the active peptide.
- **No medical supervision**: Individuals using unregulated products typically do so without dose titration or safety monitoring. This is particularly concerning for a triple receptor agonist that affects glucose metabolism, heart rate, and gastrointestinal function — and which has now shown a 21% dysesthesia rate at the 12 mg dose in Phase 3.
- **Legal concerns**: The sale of unapproved drug products is illegal in many jurisdictions. Products shipped internationally may be seized at customs.

### Compounding Pharmacy Warning

Unlike semaglutide and tirzepatide, which have been subject to FDA drug shortage designations that temporarily allowed certain compounding, **retatrutide has never been approved and therefore is not listed in any drug shortage database**. Compounding pharmacies that produce products labeled as retatrutide are operating entirely outside the regulatory framework.

There is no legitimate basis for any compounding pharmacy to produce retatrutide. Any such product:

- Is not FDA-approved or FDA-regulated
- Has not been tested for safety, purity, or efficacy
- May not contain retatrutide at all, or may contain incorrect quantities
- Carries unknown impurity and contamination risks

### Our Recommendation

This publication does not endorse or encourage the use of retatrutide from any source other than authorized clinical trials. The risk-benefit calculation for an investigational drug can only be properly assessed within a clinical trial framework where participants receive properly manufactured drug product, undergo appropriate screening and monitoring, and contribute to the data that will ultimately inform regulatory decisions.

## What Should Patients Do Now?

While waiting for retatrutide to potentially become available, patients interested in effective weight management have several options:

- **FDA-approved medications**: Semaglutide (Wegovy), tirzepatide (Zepbound), and other approved anti-obesity medications are available by prescription
- **Clinical trials**: Beyond retatrutide, numerous obesity clinical trials are enrolling participants for various investigational treatments
- **Comprehensive care**: Behavioral modification, dietary counseling, and exercise programs remain foundational to weight management
- **Discuss with your provider**: Healthcare professionals can help develop a treatment plan using currently available options while monitoring the retatrutide development timeline

## Frequently Asked Questions

### Can my doctor prescribe retatrutide?

No. Because retatrutide is not approved, it cannot be prescribed. It is available only through authorized clinical trials.

### When will retatrutide be available?

The earliest realistic availability, assuming successful Phase 3 trials and regulatory approval, would be mid-2027 to early 2028, based on Eli Lilly's Q4 2025 earnings guidance indicating NDA filing in late 2026. This timeline is subject to change based on clinical trial outcomes and regulatory decisions.

### Is retatrutide the same as tirzepatide?

No. While both are incretin-based peptide therapies developed by Eli Lilly, they are different molecules. Tirzepatide (marketed as Mounjaro and Zepbound) is a dual GIP/GLP-1 receptor agonist that is approved and commercially available. Retatrutide is a triple GIP/GLP-1/glucagon receptor agonist that remains investigational.

### Are the peptides sold online legitimate?

Products sold as retatrutide outside of clinical trials are not approved pharmaceutical products. Their quality, purity, and safety cannot be assured, and their use carries significant risks. There is no FDA drug shortage designation for retatrutide, so compounding pharmacies have no regulatory basis to produce it.

### Did TRIUMPH-4 results mean approval is coming soon?

TRIUMPH-4 demonstrated impressive efficacy (-28.7% weight loss), but one Phase 3 trial is not sufficient for an NDA. Eli Lilly needs data from additional pivotal trials, a complete safety database, and characterization of the dysesthesia signal before filing for approval. With NDA filing expected in late 2026, approval could come as early as mid-2027 with Priority Review, or late 2027 to early 2028 under standard review.

## Summary

Retatrutide is not approved by any regulatory authority as of May 2026. It is in late-stage Phase 3 clinical development through the TRIUMPH program, with three positive pivotal readouts in hand (TRIUMPH-4, TRANSCEND-T2D-1, TRIUMPH-1). NDA filing is expected in late 2026 to Q1 2027, with potential FDA approval in late 2027 to early 2028. TRIUMPH-2 and TRIUMPH-3 readouts are expected through the second half of 2026 and will round out the regulatory package.

There is no legitimate commercial source for retatrutide outside of clinical trials. Individuals interested in retatrutide should consult ClinicalTrials.gov for trial enrollment opportunities, discuss currently approved treatment options with their healthcare providers, and avoid unregulated sources that pose substantial safety and quality risks. The FDA has issued multiple warning letters to compounders attempting to sell unapproved retatrutide; retatrutide does not qualify for 503A or 503B compounding exemptions.